Discovery Labs Prices $23.5 Million Public Offering of Common Stock and Warrants
February 16, 2011 09:10 ET
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Feb. 16, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that it has priced an underwritten public offering of 10,000,000 units at a price to the...
Discovery Labs Announces Proposed Public Offering of Common Stock and Warrants
February 15, 2011 16:02 ET
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Feb. 15, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that it intends to offer, subject to market and other conditions, shares of its common...
Discovery Labs Provides Expanded Update Regarding Its Program for Surfaxin(R) U.S. Marketing Authorization
February 01, 2011 07:00 ET
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Feb. 1, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) is providing an expanded update regarding ongoing efforts to file a Complete Response intended to gain U.S....
Discovery Labs to Host a Conference Call to Provide an Overview of Its Program for Surfaxin(R) U.S. Marketing Authorization
January 27, 2011 08:00 ET
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Jan. 27, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) will host a conference call on Tuesday, February 1, 2011, at 10:00 AM EST. Management will provide an...
Discovery Labs Receives U.S. Patent Covering Pulmonary Surfactant and Protease Inhibitor Combination Products for Pulmonary Conditions
January 19, 2011 07:30 ET
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Jan. 19, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCOD) has been notified that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent...
Discovery Labs Announces that Nasdaq Hearing Panel Has Granted Request for Continued Listing on The NASDAQ Capital Market(R)
January 12, 2011 07:30 ET
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Jan. 12, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCOD) announced today that, on January 11, 2011, a NASDAQ Listing Qualifications Panel (the "Panel") determined...
Discovery Labs Provides Update Regarding Its Program for Surfaxin(R) U.S. Marketing Authorization
January 10, 2011 07:30 ET
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Jan. 10, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCOD), a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an...
Discovery Labs Announces Reverse Stock Split
December 27, 2010 17:00 ET
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Dec. 27, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of...
NIH Awards Discovery Labs Fast Track SBIR Grant to Support Development of Aerosolized KL4 Surfactant
December 16, 2010 07:00 ET
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Dec. 16, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that the Company has been awarded Phase I of a Fast Track Small Business Innovation...
Discovery Labs Aerosurf(R) Improves Lung Function and Reduces Inflammation in a Dose-Dependent Fashion in Established Non-Clinical Model of Preterm Respiratory Distress Syndrome
December 07, 2010 08:30 ET
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Dec. 7, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), today announced that new Aerosurf® data in a study employing the well-established preterm lamb model...